CAMBRIDGE, Mass., June 4, 2018— Tiba Biotech, a pre-clinical biotechnology company developing next generation RNA vaccines for human and animal health, today announced that Christian W. Mandl Ph.D., M.D., an internationally renowned molecular and clinical virologist, has been appointed as Chairman of Tiba’s Scientific Advisory Board. Today’s designation expands upon Mandl’s existing role as Co-founder and Senior Scientific Advisor, Tiba Biotech, as he will take an active role in shaping the Company’s R&D strategy.
X-HUB Tokyo and CIC’s new Venture Cafe Tokyo hosted a panel of US venture capitalists to discuss current trends in the industry. NewBridge Founder and Managing Partner, Karl Ruping, joined the panel to focus on the Boston-area startup ecosystem. X-HUB TOKYO is an exchange platform where entrepreneurs and innovators from Tokyo with global aims come together with individuals involved in innovation ecosystems around the globe. Part of the global Venture Cafe network, Venture Cafe Tokyo aims to improve Japan’s innovation ecosystem by connecting innovators through attractive spaces, programs and stories.